Eiger BioPharmaceuticals Debt to Equity

The latest debt-to-equity ratio for EIGR is -2.85. That is below the Healthcare sector average of 0.34. Investors often review this figure alongside Eiger BioPharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, EIGR currently prints -2.85 for debt-to-equity ratio, while the sector average sits near 0.34. That is roughly 934.0% below the sector mean. Large gaps often invite a closer look at Eiger BioPharmaceuticals's growth, margins, and balance sheet.

A debt-to-equity ratio of -2.85 for Eiger BioPharmaceuticals is not 'good' or 'bad' on its own. Compare it with the peer average (0.34) and with EIGR's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting EIGR's debt-to-equity ratio (-2.85), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Eiger BioPharmaceuticals's debt-to-equity ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.